

May 31, 2024

BSE Limited P J Towers, Dalal Street, <u>Mumbai-400001</u>	Code: 532321	National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>
--	---------------------	--

Re.: Acquisition of shares of Zydus Medtech Private Limited

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) read with SEBI Circular dated July 13, 2023

Dear Sir / Madam,

Board of Directors of Zydus Animal Health and Investments Limited, a wholly owned subsidiary of Zydus Lifesciences Limited, has approved the Share Purchase Agreement (“SPA”) amongst Zydus Hospitals and Healthcare Research Private Limited (“the **Seller**”), Zydus Animal Health and Investments Limited (“the **Purchaser**”) and Zydus Medtech Private Limited (“the **Target Company**”) for acquiring 10,000 (Ten Thousand) equity shares of Rs. 10/- (Rupees Ten only) each fully paid-up (“**Sale Shares**”) of the Target Company, representing 100% of the paid-up share capital, from the Seller at a consideration of Rs. 1,00,000/- (Rupees One Lac only).

Board meeting of the Purchaser commenced at 4.00 p.m. and concluded at 4.20 p.m.

Parties to the SPA have executed the SPA. Also, the consideration amount is paid by the Purchaser to the Seller and the transaction of acquisition of Sale Shares is completed. Pursuant to that, the Target Company has become the wholly owned subsidiary of the Purchaser.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 1.1 of the SEBI Circular dated July 13, 2023 are provided in **Annexure-“1”**.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **Zydus Lifesciences Limited**

Dhaval N. Soni
Company Secretary

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure-“1”

Sr. No.	Particulars	Responses
a.	name of the target entity, details in brief such as size, turnover etc.;	<p>Name of the Target Company: Zydus Medtech Private Limited, which was incorporated on January 24, 2024.</p> <p>Authorized Share Capital: Rs. 1,00,000/- (Rupees One Lac only) divided into 10,000 (Ten Thousand) equity shares of Rs. 10/- (Rupees Ten only).</p> <p>Issued, subscribed and paid-up Share Capital: Rs. 1,00,000/- (Rupees One Lac only) divided into 10,000 (Ten Thousand) equity shares of Rs. 10/- (Rupees Ten only) fully paid-up.</p> <p>Turnover: Nil</p>
b.	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>The transaction will fall under related party transaction. Zydus Lifesciences Limited, the holding company of the Purchaser, is a related party of the Seller. The proposed acquisition is at arm’s length price.</p> <p>Certain promoters of Zydus Lifesciences Limited, the holding company are the shareholders of the Seller.</p>
c.	industry to which the entity being acquired belongs;	Medical and surgical devices.
d.	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition will enable the Purchaser to explore the medical and surgical devices segment.
e.	brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable
f.	indicative time period for completion of the acquisition;	The transaction of acquisition is completed today i.e. May 31, 2024.

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Sr. No.	Particulars	Responses
g.	consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
h.	cost of acquisition and/or the price at which the shares are acquired;	Rs. 1,00,000/- (Rupees One Lac only). The Sale Shares shall be acquired at face value of Rs. 10/- (Rupees Ten only) each.
i.	percentage of shareholding / control acquired and / or number of shares acquired;	10,000 (Ten Thousand) equity shares of Rs. 10/- (Rupees Ten only) each representing 100% shares of the Target Company.
j.	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Brief Background: The Target Company was incorporated on January 24, 2024 in Ahmedabad, Gujarat, India. Last 3 years turnover: Not applicable

For, Zydus Lifesciences Limited

Dhaval N. Soni
Company Secretary

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

